📅 PUBMED DAILY TRIAGE — 2026-06-06

Window: 2026-06-05T09:00:00Z → 2026-06-06T09:00:00Z (CRDT) Topics scanned: 10 | Candidates reviewed: ~72 unique | Articles classified: 16 High priority: 5 | Standard: 11 | Low/archive: 4 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

T7 · Cardiovascular-Metabolic (GLP-1/SGLT2)

TR-2026-06-06-001 / PMID 42249138 · Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial · 10/10 🟠 NOVEL_TREATMENT

Phase 2b RCT in Nature Medicine of aleniglipron, a non-peptide small-molecule oral GLP-1 RA — first clinical proof-of-concept for an entirely new drug class that could eliminate the injection barrier to GLP-1 therapy for obesity. If Phase 3 confirms, this is a potential paradigm shift for cardiometabolic treatment access.

T4 · AI/ML in Clinical Diagnostics

TR-2026-06-06-002 / PMID 42248714 · Deep learning for H&E-based meningioma molecular classification and outcome prediction: a retrospective cohort study · 9/10 🟢 NEAR_TERM_IMPLEMENTABLE

Lancet Digital Health retrospective cohort demonstrating H&E-slide DL can predict WHO molecular meningioma subtype + outcomes — potentially replacing expensive molecular profiling panels in labs without genomics infrastructure. Directly addresses cost and access barriers in neuro-oncology staging.

T3+T5 · Liquid Biopsy / Precision Oncology (crossover)

TR-2026-06-06-003 / PMID 42248549 · Pitfalls in detecting MET exon 14 skipping variants by DNA- and RNA-based NGS in a large real-world cohort and results of the first multinational EQA schemes · 9/10 🟢 NEAR_TERM_IMPLEMENTABLE

J Mol Diagnostics large real-world cohort + first multinational EQA for MET exon 14 — a fully-approved NSCLC treatment target (capmatinib, tepotinib). Identifies DNA-NGS blind spots requiring RNA complement; directly actionable for lab protocol updates and accreditation.

T2 · CBC/ML in Hematology

TR-2026-06-06-004 / PMID 42247415 · Performance Evaluation of GPT-5, Grok 4, and DeepSeek R1 in Interpreting Complete Blood Count Reports for Hematologic Diseases: Retrospective Comparative Study · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE

J Med Internet Research retrospective comparative study — first head-to-head benchmark of frontier-generation LLMs (GPT-5, Grok 4, DeepSeek R1) on CBC interpretation for hematologic disease. Directly informs AI-assisted CBC deployment decisions across the most ordered lab test in medicine.

T1+T5 · Hematologic / Genomics (crossover)

TR-2026-06-06-005 / PMID 42248868 · Targeted reflex RNA sequencing for enhanced variant classification on exome and genome sequencing improves patient outcomes · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE

NPJ Genomic Medicine clinical validation showing targeted RNA reflex testing resolves VUS in exome/genome sequencing and demonstrably improves patient outcomes — rare outcome-linked validation in genomics. Scalable protocol for reducing diagnostic uncertainty and odyssey in rare/hereditary conditions.

🟢⚪ STANDARD (5-7) — Top by Topic

T1 · Hematologic Malignancies

• TR-2026-06-06-008 / PMID 42249165 · PET/CT vs flow cytometry vs biopsy for MCL bone marrow involvement · 6/10 · Diagnostics — Ann Hematol comparative review; both complementary modalities add value over biopsy alone
• TR-2026-06-06-007 / PMID 42249084 · Allogeneic transplant pathways in MDS/AML: survey of German-speaking centers · 6/10 · Treatment Innovation — Practice variation survey; useful for trial design context
• T1 best score: 8/10 (crossover article TR-005 filed under T5 primary)

T3 · Liquid Biopsy / ctDNA

• TR-2026-06-06-009 / PMID 42247113 · Long-read sequencing for germline+somatic variant detection in hereditary cancer · 6/10 · Genomics — Clin Transl Oncol; promising multi-modal approach, exploratory stage

T4 · AI/ML Diagnostics

• TR-2026-06-06-006 / PMID 42249154 · Explainable AI reveals U-shaped PD-L1 patterns as NSCLC immunotherapy predictors · 6/10 · Treatment Innovation/Dx — XAI on neoadjuvant IO; U-shaped PD-L1 novel if confirmed
• TR-2026-06-06-011 / PMID 42248565 · Hyperspectral imaging for breast-conserving surgery margin assessment · 6/10 · Diagnostics — Arch Pathol Lab Med systematic review; addresses high re-excision rate
• TR-2026-06-06-015 / PMID 42248793 · Deep multi-task attention network for carotid plaque quantification in ultrasound · 6/10 · Diagnostics — Automated CVD risk assessment

T6 · Novel Therapeutics

• TR-2026-06-06-014 / PMID 42249376 · Immune checkpoint blockades in melanoma: mechanism and clinical translation · 5/10 · Treatment Innovation — Mol Cancer review; background reference for ICB/melanoma pipeline
• T6: No pure T6 HIGH this run; best score 6/10

T7 · Cardiovascular-Metabolic

• TR-2026-06-06-010 / PMID 42249237 · Bariatric surgery vs dietary counseling: de novo cancer risk in propensity-matched multicenter analysis · 7/10 · Prevention — Supports obesity surgery cancer prevention benefit
• TR-2026-06-06-016 / PMID 42249426 · APOSCREEN-1: pharmacy-based CKM screening trial protocol · 6/10 · Prevention — Novel community screening implementation model

T8 · Aging/Longevity

• TR-2026-06-06-012 / PMID 42249480 · Immunological consequences of senescence in physiology and pathology · 6/10 · Other — J Transl Med review; SASP-immunity-aging mechanistic overview
• T8: No HIGH this run (filter diagnostic run; see notes)

T9 · Rare Diseases

• TR-2026-06-06-013 / PMID 42246937 · Cognitive/behavioral outcome assessments in DEE (developmental epileptic encephalopathies) · 7/10 · Other — Epilepsia review; COA gaps directly relevant to DEE drug development 🟡 UNDERSERVED

💡 UNSOLICITED FINDS

None this run. Sentinel (30 raw, PT-filtered) yielded Frontiers systematic reviews on acupuncture/ICU sedation/antimicrobial resistance — no watchlist-relevant or high-signal out-of-scope articles identified.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 6 articles
• Treatment Innovation: 4 articles
• Genomics/Precision Medicine: 2 articles
• Drug Development: 1 article
• Prevention: 3 articles

By evidence maturity:

• Validated: 6 articles (incl. 1 Phase 2b RCT, 1 retrospective cohort, 3 validation studies, 1 propensity-matched analysis)
• Exploratory: 10 articles (reviews, protocol papers, preliminary studies)

By watchlist topic (reviewed / kept / highest score):

*Unfiltered diagnostic run; filter inversion bug documented.

By source type: peer_reviewed: 16 | preprint: 0

Topics with zero 8+ articles this run: T6 (Novel Therapeutics), T8 (Aging — filter issue), T9 (Rare Diseases)

🔧 RUN NOTES

⚠️ T8 Filter Inversion Bug (Third Consecutive Run):

• NOT (animals[MeSH] NOT humans[MeSH]) was AGAIN incorrectly parsed by NCBI, returning 2 animal-only records instead of human-relevant results
• Unfiltered diagnostic search (250 raw) confirms T8 content exists — topic is not truly empty
• Recommended fix (next run): Use AND (clinical[tiab] OR patient[tiab] OR human[tiab]) NOT animals[MeSH] — avoid the double-NOT wrapper
• The unfiltered run brought significant noise (dental, parasitology) but 5 aging-relevant articles were recoverable after manual filtering
• MeSH indexing lag for fresh records is confirmed as a secondary factor; textword-based filters more reliable for CRDT-recent articles

T8 Note: PMID 42248718 (Trends Cell Biol — "Telomere heterochromatin-mediated compartmentalization: Where ALT begins") appeared in T1 hematologic search but is primarily a basic science telomere biology article; excluded from T1 (not hematologic malignancy focused). No appropriate T8 reclassification (non-clinical).

T6 Volume & Quality:

• 125 raw results, 0 HIGH after reviewing 8 — consistent with prior observation that T6 search captures too many in vitro/mechanistic studies
• Best articles were ML-immunotherapy crossovers (T4+T6) scored under T4
• Recommend adding AND (clinical[tiab] OR trial[tiab] OR patient[tiab]) to T6 query to reduce preclinical noise

Sentinel Success:

• PT filter (RCT/PhaseIII/MA/SR) reduced sentinel from 1279 to 30 — a major improvement per prior recommendation
• However, sentinel still produces watchlist-irrelevant content (acupuncture MA, ICU sedation, E. coli resistance)
• Next iteration: add combined sentinel+watchlist keyword anchor (e.g., AND (cancer OR hematol* OR GLP-1 OR aging)) to focus sentinel on pipeline-relevant signals

TOP FIND OF RUN: PMID 42249138 — Nature Medicine Phase 2b RCT of oral small-molecule GLP-1 RA aleniglipron (10/10). First non-peptide oral GLP-1 RA class with Phase 2b efficacy data.

RUNNER-UP: PMID 42248714 — Lancet Digital Health H&E-based DL meningioma molecular classification (9/10). PMID 42248549 — J Mol Diagnostics MET ex14 NGS pitfalls + first multinational EQA (9/10).

Rolling 7-day zero-HIGH topics: T8 (5 runs, filter issue), T9 (3 runs), T6 (2 runs).